8-K: TG Therapeutics Surges on Strong BRIUMVI Sales and Raised Guidance

TG Therapeutics reported robust second quarter 2026 results, driven by significant BRIUMVI revenue growth, leading to an upward revision of full-year financial targets.

Summary

• TG Therapeutics announced strong financial results for the second quarter of 2026, with total global revenue reaching approximately $240 million.
• BRIUMVI U.S. net product revenue for the quarter was approximately $228 million, a 64% increase year-over-year.
• The company raised its full-year 2026 total global revenue target to approximately $950 million and its BRIUMVI U.S. net product revenue target to $890 $905 million.
• Positive Phase 3 ENHANCE trial results were announced, supporting a simplified initiation regimen for BRIUMVI.
• Development continues for a subcutaneous formulation of BRIUMVI, with positive Phase 1 data and Phase 3 trials ongoing.
• The company also reported progress in exploring BRIUMVI for myasthenia gravis and schizophrenia, and advancement in its azer-cel cell therapy platform.
• Net income for the quarter was $7.8 million, compared to $28.2 million in the prior year period, impacted by increased R&D and SG&A expenses.
• Cash, cash equivalents, and investment securities stood at $612.3 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, driven by strong BRIUMVI performance and raised revenue guidance, indicating robust commercial execution and promising pipeline developments.

Positives

• BRIUMVI U.S. net product revenue for Q2 2026 was $227.7 million, a significant 64% increase over the prior year period.
• Total global revenue for Q2 2026 reached $240.3 million.
• Full-year 2026 total global revenue guidance raised to approximately $950 million.
• Full-year 2026 BRIUMVI U.S. net product revenue guidance raised to approximately $890 $905 million.
• Positive topline Phase 3 ENHANCE trial results announced, supporting a consolidated single infusion regimen for BRIUMVI initiation.
• Positive pharmacokinetic, pharmacodynamic, safety, and tolerability data from a Phase 1 trial for subcutaneous BRIUMVI.
• Subcutaneous BRIUMVI demonstrated mean bioavailability of greater than 60% relative to IV administration.
• Initiated Phase 2 clinical trial for BRIUMVI in treatment-resistant schizophrenia and a Phase 2 trial for BRIUMVI in myasthenia gravis.

Negatives

• Net income for the three months ended June 30, 2026, was $7.8 million, a decrease from $28.2 million in the same period of 2025.
• Total research and development (R&D) expense increased to $95.3 million for Q2 2026 from $31.8 million in Q2 2025, largely due to subcutaneous manufacturing costs.
• Total selling, general and administrative (SG&A) expense increased to $82.1 million for Q2 2026 from $55.6 million in Q2 2025, driven by increased marketing and personnel costs.
• Interest expense increased to $16.6 million for Q2 2026 from $6.7 million in Q2 2025.

Risks

• The risk that trends in prescriptions are not maintained or that prescriptions are not filled.
• Failure to obtain and maintain payor coverage for BRIUMVI.
• The risk that healthcare professional interest in BRIUMVI will not be sustained.
• The risk that momentum in sales for BRIUMVI will not be sustained.
• The risk that BRIUMVI revenue targets will not be achieved.
• Potential for variations from projections due to regulatory limitations on labeling.
• Reliance on third parties for manufacturing, distribution, and supply chain functions.
• The risk that clinical trial data readouts may be delayed due to enrollment, data collection, or data maturity.

Future Outlook

The company has raised its full-year 2026 total global revenue target to approximately $950 million and its BRIUMVI U.S. net product revenue target to approximately $890 $905 million. Operating expenses for 2026 are projected between $350 $400 million, excluding non-cash compensation, plus approximately $100 million for subcutaneous BRIUMVI manufacturing and secondary manufacturer start-up costs. The company anticipates its current cash position, combined with projected revenues, will be sufficient to fund its business based on the current operating plan.

Management Comments

• "The second quarter of 2026 was another strong quarter for TG Therapeutics. BRIUMVI delivered another outstanding commercial quarter, exceeding our expectations once again and putting us on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate."
• "Beyond our commercial performance, we continued to expand the long-term opportunity for BRIUMVI with positive Phase 3 ENHANCE results supporting a simplified initiation regimen, encouraging progress in our subcutaneous BRIUMVI program, advancement into myasthenia gravis and schizophrenia, and continued momentum across our azer-cel cell therapy platform."
• "As BRIUMVI continues to grow, it is becoming the foundation of a broader company focused on advancing innovative therapies for immune-mediated diseases. The progress we made this quarter reinforces our confidence in our strategy and our ability to create long-term value for both patients and shareholders."

Industry Context

StockSavvy.ai notes that TG Therapeutics' strong performance with BRIUMVI in the relapsing forms of multiple sclerosis (RMS) aligns with the broader trend of increasing demand for targeted therapies in autoimmune diseases. The company's strategic expansion into new indications like myasthenia gravis and schizophrenia, alongside the development of a subcutaneous formulation, reflects a common strategy in the pharmaceutical sector to maximize the value of a successful drug and address unmet patient needs.

Comparison to Industry Standards

• BRIUMVI's Q2 2026 U.S. net product revenue of $227.7 million represents a 64% year-over-year increase, which is a strong growth rate compared to many established therapies in the MS market.
• The raised full-year revenue guidance to $950 million indicates that BRIUMVI is achieving significant market penetration, potentially rivaling or exceeding the initial commercial performance of some competitor products in their early stages.
• The development of a subcutaneous formulation is a common industry practice to improve patient convenience and potentially expand market share, as seen with other biologics across various therapeutic areas.
• The company's R&D expenses, while increasing, are in line with the investment required for late-stage clinical trials and pipeline expansion typical for a commercial-stage biotechnology company.

Stakeholder Impact

• Shareholders: Positive impact expected from raised revenue guidance and strong commercial performance of BRIUMVI, potentially leading to increased shareholder value.
• Patients: Continued access to BRIUMVI for RMS, with potential for improved treatment initiation via the consolidated infusion regimen and future options like subcutaneous administration.
• Healthcare Professionals: Potential for simplified treatment protocols with the ENHANCE trial results and ongoing development of new formulations and indications.
• Suppliers: Continued demand for manufacturing and supply chain services related to BRIUMVI production.

Next Steps

• Present full results from the Phase 3 ENHANCE trial combining Day 1 and Day 15 doses of IV BRIUMVI.
• Present preliminary Phase 1 azer-cel data in Progressive MS in the second half of 2026.
• Announce topline Phase 3 data for subcutaneous BRIUMVI by year-end 2026 or first quarter 2027.
• Continue to monitor and manage BRIUMVI commercialization and pipeline development.

Key Dates

Recommendation

The strong commercial execution of BRIUMVI, evidenced by significant revenue growth and raised guidance, coupled with positive clinical trial data and pipeline advancements, presents a compelling investment case. The company's financial health appears robust, and strategic developments suggest continued growth potential, warranting a strong buy recommendation.

Keywords

BRIUMVI, ublituximab, Multiple Sclerosis, RMS, biotechnology, oncology, clinical trials, revenue guidance